Sponsor Pipeline

Tenax Therapeutics, Inc. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
3
Active Trials
1
Recruiting
3
Phase 3
2
Disease Areas
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-07-22 NCT05983250
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF		 overall status: Recruiting → Active, Not Recruiting
2026-07-22 NCT05983250
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF		 date change Primary completion moved earlier: 2026-10 -> 2026-06-16
Active Trials by Phase
Phase 3
3
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT07288398 LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 Pulmonary Hypertension Associated With HFpEF Recruiting
NCT07436689 Long-Term Open-Label Extension Study of Oral Levosimendan Pulmonary Hypertension Associated With HFpEF Enrolling by Invitation
NCT05983250 LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF Pulmonary Hypertension Active, Not Recruiting
Disease Areas
Hypertension (3) Heart Failure (2)
Get alerts when Tenax Therapeutics, Inc.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free